Pharmaceutical sponsor
Boston Scientific Corporation Clinical Trials
Studies where Boston Scientific Corporation is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 39Obesity
Safety and Effectiveness of Orbera365™ Intragastric Balloon System
This is a prospective, multi-center, standard of care registry offered to subjects in the EU only that have already agreed to receive the Orbera365™ Intragastric Balloon (IGB) System for weight loss.
- Trial name
- Orbera365 (NCT07062094)
- Testing
- Intragastric Balloon
- Where
- 4 sites in Czechia, Spain and 1 more
- Volunteers
- 200 people
- Sponsor
- Boston Scientific Corporation
Heart Failure - NYHA II - IV
Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
This study will compare two different methods to pace the heart to treat heart failure including: 1. The current standard method of implanting a pacing lead in a vein on the surface of the left lower chamber of the heart (left…
- Trial name
- SYNCHRONICITY (NCT07069738)
- Testing
- CRT-D with a Quadripolar LV lead, CRT-D with INGEVITY+ pace/sense lead
- Where
- 43 sites in United States
- Volunteers
- 850 people
- Sponsor
- Boston Scientific Corporation
Cardiac Disease
BoStOn SCientific Rhythm MAnagemenT REgiStry
SOCRATES is part of Boston Scientific's (BSC) Post-market surveillance system. The implementation of such systems is mandatory per local regulations such as the Regulation '(EU) 2017/745 of the European Parliament and of the…
- Trial name
- SOCRATES (NCT04823663)
- Testing
- Implant, Electrophysiologic procedure
- Where
- 26 sites in Belgium, Canada and 8 more
- Volunteers
- 12,500 people
- Sponsor
- Boston Scientific Corporation
Carotid Artery Stenosis
A Prospective, Multicenter, Single Arm Registry of ENROUTE NPS in Conjunction With Carotid WALLSTENT in Chinese Population
The study is a prospective, non-randomized, single-arm, multi-center registry to confirm the safe delivery of the Carotid WALLSTENT Endoprosthesis when used with the ENROUTE® Transcarotid Neuroprotection System in the Chinese…
- Trial name
- ASCENT-C (NCT07458243)
- Testing
- transcarotid artery revascularization
- Volunteers
- 60 people
- Sponsor
- Boston Scientific Corporation
Glioblastoma Multiforme, Recurrent Glioblastoma
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
- Trial name
- FRONTIER (NCT05303467)
- Testing
- TheraSphere GBM
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- Boston Scientific Corporation
Motor Epilepsy
Combined CM and STN Stimulation for Motor Epilepsy
This self-crossover, randomized controlled, pilot study aims to collect clinical data of bilateral stimulation of subthalamic nucleus (STN) combined with centromedian (CM) thalamus deep brain stimulation (DBS) for drug resistant…
- Trial name
- CoSMos (NCT07458217)
- Testing
- Deep brain stimulation
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Boston Scientific Corporation
Hepatocellular Carcinoma (HCC)
A Post Approval Study to Evaluate Safety and Effectiveness of Multicompartmental Dosimetry Planning.
The purpose of this study is to assess the safety and effectiveness of treating a tumor using a different planning method called MCD for the FDA-Approved device, TheraSphere.
- Trial name
- ADVANCE-MCD (NCT07669727)
- Testing
- TheraSphere
- Volunteers
- 140 people
- Sponsor
- Boston Scientific Corporation
Atrial Fibrillation (AF), Stroke Prevention in Patients With Atrial Fibrillation
OPTION-EMEA Clinical Trial
The OPTION-EMEA post-market study is intended to gather real world clinical data for patients undergoing AF ablation with the FARAPULSE™ Pulsed Field Ablation (PFA) System and subsequent left atrial appendage closure (LAAC) with…
- Conditions
- Atrial Fibrillation (AF), Stroke Prevention in Patients With Atrial Fibrillation, Left Atrial Appendage Closure, Pulsed Field Ablation
- Trial name
- OPTION-EMEA (NCT07349121)
- Testing
- Concomitant pulsed field ablation (PFA) and left atrial appendage closure (LAAC) during one interventional case, Concomitant Pulsed Field Ablation and Left Atrial Appendage Closure
- Where
- 11 sites in Belgium, Croatia and 3 more
- Volunteers
- 500 people
- Sponsor
- Boston Scientific Corporation
Weight Loss
OverStitch NXT Endoscopic Suture System
To demonstrate the safety and efficacy of OverStitch NXT Endoscopic Suture System for endoscopic sleeve gastroplasty（ESG） in obese populations to support the registration of OverStitch NXT for ESG indication.
- Trial name
- NCT07276815
- Testing
- OverStitch NXT Endoscopic Suture System
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Boston Scientific Corporation
Weight Loss
Orbera365 Intragastric Balloon System (Abbreviated as'Orbera365')
To demonstrate the safety and efficacy of Orbera365 in obese populations to support the registration of Orbera365.
- Trial name
- NCT07195708
- Testing
- Treatment group
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Boston Scientific Corporation
Completed, with results posted
All 244Parkinson Disease
Closed Loop Programming Evaluation Using External Responses for Deep Brain Stimulation
The objective of this study is to evaluate the performance of novel DBS programming methods compared to traditional programming methods.
- Trial name
- CLOVER (NCT03037398)
- Testing
- Vercise Deep Brain Stimulation System
- Where
- 3 sites in Germany
- Volunteers
- 69 people
- Sponsor
- Boston Scientific Corporation
ACC/AHA/NASPE Class 1, IIa or IIb Indications
Subcutaneous Implantable Defibrillator (S-ICD) System - CE Clinical Investigation
The primary objective is to evaluate the S-ICD system's ability to identify and terminate induced ventricular fibrillation in patients during the implant procedure.
- Trial name
- NCT01117792
- Testing
- subcutaneous implantable defibrillator (S-ICD) system
- Where
- 8 sites in Italy, Netherlands and 2 more
- Volunteers
- 55 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
Safety and Effectiveness of Agent Paclitaxel-Coated PTCA Balloon Catheter. (AGENT Japan SV)
A Randomized Trial Comparing the Agent Paclitaxel-Coated PTCA Balloon Catheter vs SeQuent Please Drug Eluting Balloon Catheter for the Treatment of a Small Vessel De Novo Native Coronary Artery Lesion.
- Trial name
- NCT04058990
- Testing
- Device: Paclitaxel-Coated PTCA Balloon Catheter, SeQuent Please Drug Eluting Balloon Catheter with Paclitaxel
- Where
- 14 sites in Japan
- Volunteers
- 180 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
PROMUS PREMIER™ China Post-Approval Study
To compile real-world clinical outcome data for the Promus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System (Promus PREMIERTM Stent System) in routine clinical practice in China.
- Trial name
- NCT03273023
- Testing
- Promus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System
- Where
- China
- Volunteers
- 2,059 people
- Sponsor
- Boston Scientific Corporation
Pain, Chronic
Radiofrequency (RF) Ablation Prospective Outcomes Study
The objective of this study is to compile real-world outcomes of Boston Scientific commercially approved radiofrequency (RF) ablation systems in the treatment of patients diagnosed with pain
- Trial name
- RAPID (NCT04673032)
- Testing
- Radiofrequency Ablation
- Where
- 15 sites in United States, Belgium and 2 more
- Volunteers
- 298 people
- Sponsor
- Boston Scientific Corporation